Roche's presentation in HealthBIO 2016

2. Titus Gylvin
MD, PhD
General Manager
Roche Oy

3. www.roche.com
Roche is the world’s largest
biotech company
Roche’s combined strenghts in pharmaceuticals and diagnostics
have made it the leader in personalized healthcare.
Roche has brought 14 biopharmaceuticals to the market
and majority of its new molecules in development are based on
biotechnology.

5. Roche in Finland
Roche has operated in Finland since 1982
Local decision making power due to
decentralized global organization model
Employees
90 Roche Oy
75 Roche Diagnostics Oy
Ca. 30 clinical trials
in Finland (01/2016)

6. Focus areas of Roche
Oncology
Rheumatology
Neuroscience
Respiratory
Immunology and infections
Ophthalmology

7. www.roche.com
A pioneer in cancer treatment
We have developed medicines for breast cancer, skin cancer,
colorectal cancer, ovarian cancer, lung cancer and to many
other cancers.
Out of all new Roche molecules in development about half are
studied for cancer treatments.
We are studying more than 20 investigational cancer
immunotherapy medicines, nine of which are in clinical trials.

8. Roche invests to research and
development more than any other
pharmaceutical company

9. FI/ROCH/1601/0007
Roche annual investment to R&D
is four times the spending on
prescription medicines in Finland
Roche annual report 2015
Currency exhange 31.12.2015
Roche R&D investment in 2015
8,6*Billion euros (globally)
Spending on
prescription
medicines in Finland
(IMS)
2,0Billion euros

10. Roche has strong pipeline
In the next three years launches for up
to eight new medicines planned
Situation 28.1.2016 Roche reporting centre, Full year 2015 presentation,
www.roche.com Roche annual report 2015
New molecular
entities
New
indications
70 63Phase I-IIIb Phase I-IIIb

12. Top 3
in BCG research surveys 2008- 2014
190partnerships
currently managed around
the world
33 % of our research
pipeline comes from partnered
products
35 % of total
pharmaceutical sales from partnered
and in-licensed products (CHF 12 bn
in 2014)

13. 61
Total new agreements
in 2015
4
acquistions
4
product transactions
45
R&D collaborations
2014-2015
10,7
billion euros on acquistions

14. Basel
New York
BostonSan Francisco
Shanghai
Tokyo

15. Academic collaboration around the world
Harvard
MIT
Karolinska Insititute
Universities in Basel
Zürich
Hebrew University
50
universities

16. Roche partnerships in Finland
Helsinki University & HUS
TAYS & FinnMedi
Auria Biobank

17. When evaluating partnership prospects we consider
Cultural fit
Opportunity of the new technology
Focus on our main disease areas
Potential to revolutionise the standard of
care
Potential to be first in class or best in class

18. How to find us
http://www.roche.com/partnering/get_in_touch_with_us/partnering_contact_us.htm

19. FI/ROCH/1601/000